BAUDETTE, Minn. / Apr 26, 2023 / Business Wire / ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ Headquarters in New York City as follows:
Date: | Tuesday, May 2, 2023 | ||||||
Time: | 12:00 p.m. ET | ||||||
Webcast: | Click Here |
The webcast will be accessible on demand beginning on May 3, 2023, at 7:00 a.m. ET and archived for 90 days thereafter, via the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.
Last Trade: | US$92.53 |
Daily Change: | 0.65 0.71 |
Daily Volume: | 387,078 |
Market Cap: | US$2.010B |
August 25, 2025 August 08, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load